Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Cara Therapeutics lifted by positive results from phase 2 to 3 trial results of treatment for uremic pruritus

Tuesday, March 28, 2017 6:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in Cara Therapeutics Inc (NASDAQ:CARA) jumped higher after the biotech group reported positive results from a trial of a treatment for uremic pruritus, a debilitating itch condition that affects patients with chronic kidney disease.

In a statement, the company said that results from Part A of a phase 2 to 3 trial of its I.V. CR845 treatment met primary and secondary endpoints for efficacy.

It noted that there are currently no approved therapies for the condition in the US.

Gil Yosipovitch, Professor of dermatology at the Miller School of Medicine and director of the Miami Itch Center at the University of Miami said: “There is an unmet medical need for an effective long-term therapy for treating this intractable pruritus and providing meaningful improvement in the quality of life of these patients under dialysis treatment.”

The company said it is planning to meet with the US Food and Drug Administration to finalise the design of Part B of the study and to start recruiting patients later this year.

CR845 is being developed for the treatment of acute and chronic pain as well as uremic pruritus.

In premarket trading in New York, Cara shares were over 15% higher at US$20.63, having gained 95% in the year to date.

Story by ProactiveInvestors


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.